+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial

Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial

Bmc Ophthalmology 15: 35

The recurrence rate of periocular nodular basal cell carcinoma (PNBCC) following treatment with imiquimod (IMQ) has not yet been established. Previous studies did not include histological follow-up. The aim of this analysis was to evaluate the efficacy of topical immunotherapy with 5% IMQ cream for the treatment of PNBCC. A prospective, non-randomized, and uncontrolled longitudinal case series study. No participants were blinded. Punch biopsy confirmed PNBCC patients were included at the Ophthalmology Clinic of São Paulo University Medicine School Hospital (from 2008 to 2012). Patients were treated with 5% IMQ cream once a day, 5 days per week, for 8-16 weeks. Standard lesion photographic documentation was done during the study. Three months after treatment ended, an image-guided biopsy was performed. Patients were followed at 6-month intervals and annually for control biopsies. Main outcome measures were clinical and histological clearance rates. Data were analysed by frequency distribution for qualitative group characteristics and central tendency measures for quantitative data. Twenty-four patients met the inclusion criteria, 19 of whom remained until the end of treatment. The histological clearance rate was 89.5% and 84.2%, respectively, at 3 and 39.5 months. The 3-year histological clearance rate was 81.8% (9/11) for lesions >10 mm, and 100% (8/8) for lesions <10 mm. Three patients did not tolerate the side effects of the medication and left the study. Two patients were excluded for treatment interruption related to comorbidities. Our results indicated that 5% IMQ cream was a useful alternative treatment for NBBCC, especially for lesions <10 mm. IMQ also showed a significant neoadjuvant effect on lesions >10 mm. ClinicalTrial.gov Registration Dec 3, 2008: # NCT 00803907.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058048729

Download citation: RISBibTeXText

PMID: 25885553

DOI: 10.1186/s12886-015-0024-0

Related references

A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. Journal of the American Academy of Dermatology 57(4): 616-621, 2007

Imiquimod 5% Cream as Pre-Treatment of Mohs Micrographic Surgery for Nodular Basal Cell Carcinoma in the Face, A Prospective Randomized Controlled Study Imiquimod As Pre-Treatment of Mohs. 2012

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology 138(9): 1165-1171, 2002

Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma. Ophthalmic Plastic and Reconstructive Surgery 26(2): 100-102, 2010

Re: "Imiquimod 5% cream for the treatment of periocular basal cell carcinoma". Ophthalmic Plastic and Reconstructive Surgery 27(4): 305; Author Reply 305-6, 2011

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion. British Journal of Dermatology 147(6): 1227-1236, 2002

An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australasian Journal of Dermatology 47(1): 46-48, 2006

Imiquimod 5% cream as an adjuvant pre-operative treatment for basal cell carcinoma of the periocular area. Orbit 33(6): 471-473, 2014

The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. Trials 11: 42, 2010

Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma. Dermatology Nursing 21(2): 86-87, 2009

Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study. British Journal of Dermatology 167(1): 110-115, 2012

Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas. Journal of Ocular Pharmacology and Therapeutics 26(4): 373-379, 2010

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area. Indian Journal of Ophthalmology 65(1): 48-51, 2017

Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream. Dermatology Online Journal 14(2): 25, 2008

Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet. Oncology 15(1): 96, 2014